OncoMatch/Clinical Trials/NCT06371157

A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma

Is NCT06371157 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including AK104 and Lenvatinib for hepatocellular carcinoma.

Phase 3RecruitingAkesoNCT06371157Data as of May 2026

Treatment: AK104 · Lenvatinib — A study to evaluate cadonilimab (AK104) + lenvatinib in combination with transarterial chemoembolization (TACE) versus TACE in participants with incurable/non-metastatic hepatocellular carcinoma

Check if I qualify

Extracted eligibility criteria

Cancer type

Hepatocellular Carcinoma

Disease stage

Excluded: Stage IV

No evidence of metastasis; Not amenable to curative surgery or transplantation or curative ablation but amenable to TACE

Performance status

ECOG 0–1(Restricted strenuous activity)

Lab requirements

Liver function

child pugh score class a

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify